利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.021 秒)

    PROCESS FOR PREPARING AND PURIFYING FATTY ACIDS
    1.
    发明申请
    PROCESS FOR PREPARING AND PURIFYING FATTY ACIDS 有权
    制备和净化脂肪酸的方法

    公开(公告)号：US20130150602A1

    公开(公告)日：2013-06-13

    申请号：US13574634

    申请日：2011-01-27

    申请人： Adam Kelliher ,  Angus Morrison ,  Phil Knowles

    发明人： Adam Kelliher ,  Angus Morrison ,  Phil Knowles

    IPC分类号： C07C51/487 ,  C07C51/38

    CPC分类号： C07C51/487 ,  C07C51/38 ,  C07C51/41 ,  C07C51/412 ,  C07C51/42 ,  C07C51/48 ,  C07C53/126 ,  C07C57/02

    摘要： There is provided a process for purifying a fatty acid, which process comprises reacting a fatty acid with a lithium salt in a first solution and under conditions to allow formation of a precipitate of a lithium salt of the fatty acid; isolating the precipitate; dissolving the precipitate in a second solution followed by separation of the organic and aqueous layers so formed; and evaporating the organic layer to isolate the purified fatty acid. There is also provided a process for increasing the length of a fatty acid, and the use of a lithium salt to purify a fatty acid.

    摘要翻译： 提供了一种纯化脂肪酸的方法，该方法包括使第一溶液中的脂肪酸与锂盐反应，并在允许形成脂肪酸的锂盐沉淀物的条件下进行; 分离沉淀物; 将沉淀物溶解在第二溶液中，然后分离如此形成的有机层和水层; 并蒸发有机层以分离纯化的脂肪酸。 还提供了增加脂肪酸长度的方法，以及使用锂盐来纯化脂肪酸的方法。

    Process for preparing and purifying fatty acids
    3.
    发明授权
    Process for preparing and purifying fatty acids 有权
    脂肪酸的制备和纯化方法

    公开(公告)号：US09079847B2

    公开(公告)日：2015-07-14

    申请号：US13574634

    申请日：2011-01-27

    申请人： Adam Kelliher ,  Angus Morrison ,  Phil Knowles

    发明人： Adam Kelliher ,  Angus Morrison ,  Phil Knowles

    IPC分类号： C07C51/00 ,  C07C51/487 ,  C07C51/41 ,  C07C51/42 ,  C07C51/48 ,  C07C51/38

    CPC分类号： C07C51/487 ,  C07C51/38 ,  C07C51/41 ,  C07C51/412 ,  C07C51/42 ,  C07C51/48 ,  C07C53/126 ,  C07C57/02

    摘要： There is provided a process for purifying a fatty acid, which process comprises reacting a fatty acid with a lithium salt in a first solution and under conditions to allow formation of a precipitate of a lithium salt of the fatty acid; isolating the precipitate; dissolving the precipitate in a second solution followed by separation of the organic and aqueous layers so formed; and evaporating the organic layer to isolate the purified fatty acid. There is also provided a process for increasing the length of a fatty acid, and the use of a lithium salt to purify a fatty acid.

    摘要翻译： 提供了一种纯化脂肪酸的方法，该方法包括使第一溶液中的脂肪酸与锂盐反应，并在允许形成脂肪酸的锂盐沉淀物的条件下进行; 分离沉淀物; 将沉淀物溶解在第二溶液中，然后分离如此形成的有机层和水层; 并蒸发有机层以分离纯化的脂肪酸。 还提供了增加脂肪酸长度的方法，以及使用锂盐来纯化脂肪酸的方法。

    USE OF PUFAS TO TREAT NERVE DAMAGE
    7.
    发明申请
    USE OF PUFAS TO TREAT NERVE DAMAGE 审中-公开

    公开(公告)号：US20120122982A1

    公开(公告)日：2012-05-17

    申请号：US13318420

    申请日：2010-04-22

    申请人： Adam Kelliher ,  Norman Camaron ,  Angus Morrison ,  Phil Knowles

    发明人： Adam Kelliher ,  Norman Camaron ,  Angus Morrison ,  Phil Knowles

    IPC分类号： A61K31/201 ,  A61P25/00 ,  A61P25/02 ,  A61P13/10 ,  A61P31/00 ,  A61P29/00 ,  A61P15/00 ,  A61P43/00 ,  A61P1/00 ,  A61K31/202 ,  A61P21/00

    CPC分类号： A61K31/202

    摘要： The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is —(CH2)4—CH(OR2)-[trans]CH═CH-[cis]CH═CH—, —(CH2)4-[cis]CH═CH-[trans]CH═CH—CH(OR2)—, —CH(OR2)-[trans]CH═CH-[cis]CH═CH—CH2-[cis]CH═CH—(CH2)3—, —(CH2)3—CH(OR2)-[trans]CH═CH-[cis]CH═CH—CH2-[cis]CH═CH—, or —(CH2)3-[cis]CH═CH—CH2-[cis]CH═CH-[trans]CH═CH—CH(OR2)—; R1 is a hydrogen atom; or R1 is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C7 carbocyclyl or 5- to 10-membered heterocyclyl group; or R1 is a group of formula —CH2—CH(OR3)—CH2—(OR4), wherein R3 and R4 are each independently hydrogen atoms or —(C═O)—R6, wherein R6 is an aliphatic group having from 3 to 29 carbon atoms; or R1 is a group of formula —(CH2OCH2)mOH, wherein m is an integer of from 1 to 200; or R1 is a drug moiety; each R2 is the-same or different- and each independently represents a hydrogen atom; or a group —(C═O)—R5, wherein R5 is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C7 carbocyclyl or 5- to 10-membered heterocyclyl group, or R5 is an aliphatic group having from 3 to 29 carbon atoms, or R5 is a drug moiety; or a group of formula —(CH2OCH2)nOH, wherein n is an integer of from 1 to 200; or a drug moiety; and wherein said alkyl, alkenyl, alkynyl and aliphatic groups are the same or different and are each unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents which are the same or different and are selected from halogen atoms and C1-C4 alkoxy, C2-C4 alkenyloxy, C1-C4 haloalkyl, C2-C4 haloalkenyl, C1-C4 haloalkoxy, C2-C4 haloalkenyloxy, hydroxyl, —SR′, and —NR′R″ groups where R′ and R″ are the same or different and represent hydrogen or unsubstituted C1-C2 alkyl; said aryl, heteroaryl, carbocyclyl and heterocyclyl groups are the same or different and are each unsubstituted or substituted by 1, 2, 3 or 4 unsubstituted substituents which are the same or different and are selected from halogen atoms, and cyano, nitro, C1-C4 alkyl, C1-C4 alkoxy, C2-C4 alkenyl, C2-C4 alkenyloxy, C1-C4 haloalkyl, C2-C4 haloalkenyl, C1-C4 haloalkoxy, C2-C4 haloalkenyloxy, hydroxyl, C1-C4 hydroxyalkyl, —SR′ and —NR′R″ groups wherein each R′ and R″ is the same or different and represents hydrogen or unsubstituted C1-C4 alkyl; in the manufacture of a medicament for use in treating or preventing nerve damage in a mammal.